Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405.
3145 Background: SnoRNAs are non-coding RNAs that primarily guide the chemical modification of ribosomal RNA. Emerging evidence suggests snoRNAs play critical roles in cancer, including CRC, by regulating cell proliferation, apoptosis and tumor progression. Aberrant snoRNA expression has been linked to CRC development and poor prognosis, offering potential as diagnostic biomarkers and therapeutic targets. We investigated whether the tumor expression levels of 3 types of snoRNAs (SCARNA, SNORA, SNORD) affect treatment response in pts enrolled in CALGB/SWOG 80405 (NCT00265850). Methods: 433 mCRC pts treated with bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) in combination with first-line chemotherapy were analyzed. RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). 422 snoRNAs were evaluated (23 SCARNA, 140 SNORA, 259 SNORD). Overall survival (OS) and progression-free survival (PFS) were compared across tertiles of gene expression (high [H], medium [M], low [L]) by multivariable Cox proportional hazards models adjusted for age, sex, ECOG performance status, tumor side, number of metastatic sites, KRAS , CMS subtypes, and treatment. Interaction tests for the predictive effect (bev vs cet) were performed. P -values were corrected for multiple testing using the Benjamini-Hochberg approach ( q < 0.05). Results: Only SCARNA21 achieved statistical significance for OS after false discovery rate (FDR) adjustment. Tumors with H levels of SCARNA21 had shorter survival compared to tumors with M or L expression (median OS 24.4 vs 32.4 vs 33.9 months, respectively; P = 0.0015, q = 0.033), independent of treatment. No snoRNAs achieved FDR significance for PFS. However, several snoRNAs showed significant treatment interactions with biologic agents. SCARNA6-H and SCARNA5-H tumors had longer PFS and OS when treated with cet, but shorter PFS and OS when treated with bev, compared to the M and L expression groups (PFS interaction q = 0.0067 and 0.045, respectively; OS interaction q = 0.022 and 0.034, respectively). SCARNA7 also showed significant treatment interaction for OS, favoring cet in the H expression group ( q = 0.018); the opposite was observed for SNORA63B, SNORA63D, SNORA35B, and SNORA36C ( q = 0.027, 0.027, 0.027 and 0.047, respectively). No significant results were observed for any of the tested SNORDs. Conclusions: SnoRNAs dysregulation affects key pathways such as cell cycle control and immune evasion, making them promising players in CRC biology. Our study highlights the prognostic and predictive potential of specific snoRNAs in mCRC. Notably, high SCARNA21 expression was linked to shorter OS, while SCARNA5 and 6 showed predictive value for treatment response, indicating their potential for guiding treatment decisions. Further validation is needed to confirm these findings, and mechanistic studies are warranted.
Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405.
3128 Background: LncRNAs have emerged as key regulators of cancer progression and therapeutic responses. In CRC, several lncRNAs have been implicated in modulating tumor growth, metastasis and treatment resistance by interacting with critical tumorigenic pathways. Here, we investigate the potential prognostic and predictive value of lncRNA expression in patients (pts) with mCRC enrolled in CALGB/SWOG 80405 (NCT00265850) trial. Methods: We analyzed 433 mCRC pts treated with either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) plus first-line chemotherapy. Tumor RNA expression (Illumina HiSeq 2500) of 13 candidate lncRNAs (SNHG11, HOTAIR, FGF14-AS2, H19, YWHAE, NEAT1, MIR100HG, UCA1, LINC00973, SLCO4A1-AS1, POU5F1P4, MALAT1, HCG18) was explored. Median overall survival (mOS) and progression-free survival (mPFS) in months (mo) were compared between pts grouped by tertiles (low [L] vs medium [M] vs high [H]) of gene expression. Likelihood ratio tests, hazard ratios and 95% confidence intervals were computed from multivariable Cox proportional hazards models, adjusting for age, sex, ECOG PS, tumor location, number of metastatic sites, KRAS , Consensus Molecular Subtypes (CMS), and treatment. Results: Overall, SNHG11 was strongly associated with OS and PFS after adjusting for multiple tests (Benjamini-Hochberg False Discovery Rate < 0.05). High SNHG11 expression (H group, n = 144) was associated with improved mPFS (H: 14.3 vs M: 11.2 vs L: 8.3 mo; p = 0.038) and mOS (H: 39.6 vs M: 31.1 vs L: 20.5 mo; p = 0.033) in the combined treatment analysis. Among cet-treated pts, SNHG11-H showed a numerically longer mPFS (H: 14.2 vs M: 11.1 vs L: 7.6 mo; p = 0.19) and significantly longer mOS (H: 41.1 vs M: 32.4 vs L: 14.3 mo; p = 0.012). In contrast, no statistically significant OS or PFS differences were observed in bev-treated pts. SNHG11-H tumors had a significant OS benefit from cet compared to bev (mOS 41.1 vs 36.5 mo, respectively; p = 0.016), with a nominally significant treatment interaction observed for OS (p = 0.030). No significant differences were observed in the L or M expression groups. Additional analyses showed that SNHG11 expression was high in the CMS2 (canonical) subtype and substantially lower in CMS1 (immune). Conclusions: LncRNA SNHG11 plays a significant role in CRC progression and metastasis via tumorigenic pathways, including c-Myc and HIF-1α. Moreover, elevated circulating SNHG11 levels show promise as a non-invasive biomarker for early CRC detection. In CALGB/SWOG 80405, high SNHG11 expression correlated with improved PFS and OS, particularly in cet-treated pts, supporting its role as a prognostic and predictive biomarker. Its strong association with CMS2 aligns with its reported involvement in c-Myc-driven pathways. Further validation is needed to confirm the clinical utility of this biomarker and elucidate underlying mechanisms.
Impact of expression of metabolic genes on patient (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).
224 Background: Metabolic pathways are reprogrammed during CRC development, leading to increased glycolysis, glutaminolysis, and fatty acid synthesis. Understanding the impact of metabolic reprogramming on treatment outcomes is paramount. Hence, we investigated whether the tumor gene expression of 4 selected major metabolic genes ( PKM, SLC2A1 , SLC16A1 , and CAV1 ) could affect treatment response in pts enrolled in the CALGB/SWOG 80405 trial. Methods: 433 mCRC pts treated with either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) in combination with first-line chemotherapy were analyzed. RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). Overall survival (OS) and progression-free survival (PFS) were compared between groups of pts categorized by tertiles of gene expression (high [H], medium [M] and low [L]). Logrank P -values provide a non-parametric unadjusted assessment of differences. Likelihood ratio tests (LRT) were computed from multivariate Cox proportional hazards models, adjusting for age, sex, ECOG, tumor side, number of metastatic sites, KRAS , CMS, and treatment. Results: PKM gene expression was associated with cet treatment outcomes with PKM- low tumors showing significantly longer PFS and OS (median PFS: 14.3 vs 9.8 vs 8.1 months, L vs M vs H, P < 0.0001, LRT P = 0.011; median OS: 45.9 vs 31.2 vs 20.9 months, P < 0.0001, LRT P = 0.12). Low SLC2A1 was also associated with longer OS in cet-treated pts (32.4 vs 35.8 vs 25.2 months, P = 0.02, LRT P < 0.0001). Similar results were observed in bev-treated pts where low SLC2A1 expressing tumors had longer OS (37.4 vs 26.1 vs 29 months, P = 0.037, LRT P = 0.069) and a non-significant trend for longer PFS (13.1 vs 11 vs 9.5 months, P = 0.076). CAV1 low gene expression was associated with longer OS in cet-treated pts (37.4 vs 34 vs 21.5 months, P = 0.0048, LRT P = 0.013), while no significant associations were found in bev-treated (interaction LRT P = 0.0009). No significant results were observed for SLC16A1 . Conclusions: The intratumoral expression of metabolic genes was prognostic and predictive in mCRC pts treated with first-line therapy. GLUT1 (encoded by SLC2A1 ) and PKM2 (encoded by PKM ) promote aerobic glycolysis of cancer cells, known as Warburg effect, supporting rapid cell proliferation and survival. CAV1 has been shown to be involved in mitochondrial bioenergetics and fatty acid metabolism and to play either a tumor suppressor or oncogenic role depending on the cancer type and stage. Lower expression of SLC2A1 and PKM was associated with improved survival and increased benefit from cet treatment in our cohort. Low CAV1 expression was also associated with increase survival suggesting a cancer-promoting role in mCRC. Our results suggest that targeting cancer cell metabolism through novel inhibitors of the aforementioned pathways may be a promising therapeutic strategy.